Study of PolyIC and PD-1 mAb in Subjects With Unresectable Hepatocellular Carcinoma

NCT03732547 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma, Hepatocellular

Interventions

DRUG: PD-1 mAb
DRUG: PolyIC

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University